Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NCT00964171
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
19
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Efavirenz 600mg
Sponsor
Institut Bergonié